company background image
AMYT

Amryt PharmaAIM:AMYT Stock Report

Market Cap

UK£451.6m

7D

-2.0%

1Y

-25.8%

Updated

01 Dec, 2021

Data

Company Financials +
AMYT fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

AMYT Stock Overview

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases.

Amryt Pharma Competitors

Amgen

NasdaqGS:AMGN

US$112.0b

Price History & Performance

Summary of all time highs, changes and price drops for Amryt Pharma
Historical stock prices
Current Share PriceUK£1.46
52 Week HighUK£2.30
52 Week LowUK£1.36
Beta0.085
1 Month Change-9.63%
3 Month Change-10.46%
1 Year Change-25.77%
3 Year Changen/a
5 Year Changen/a
Change since IPO9.40%

Recent News & Updates

Shareholder Returns

AMYTGB PharmaceuticalsGB Market
7D-2.0%-1.6%-2.6%
1Y-25.8%8.4%10.9%

Return vs Industry: AMYT underperformed the UK Pharmaceuticals industry which returned 8.4% over the past year.

Return vs Market: AMYT underperformed the UK Market which returned 10.9% over the past year.

Price Volatility

Is AMYT's price volatile compared to industry and market?
AMYT volatility
AMYT Average Weekly Movement5.2%
Pharmaceuticals Industry Average Movement5.7%
Market Average Movement4.9%
10% most volatile stocks in GB Market9.8%
10% least volatile stocks in GB Market2.5%

Stable Share Price: AMYT is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: AMYT's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015182Joe Wileyhttps://www.amrytpharma.com

Amryt Pharma plc, a commercial-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company offers Lomitapide for the treatment of homozygous familial hypercholesterolemia; and Metreleptin for the treatment of generalized and partial lipodystrophy. It also develops FILSUVEZ drug candidate, which is in Phase 3 EASE trial for the treatment of severe epidermolysis bullosa (EB), a rare and genetic skin disease; and AP103 that is in preclinical stage for the treatment of patients with recessive dystrophic EB, a subset of EB.

Amryt Pharma Fundamentals Summary

How do Amryt Pharma's earnings and revenue compare to its market cap?
AMYT fundamental statistics
Market CapUS$601.37m
Earnings (TTM)-US$87.53m
Revenue (TTM)US$210.24m

2.9x

P/S Ratio

-7.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
AMYT income statement (TTM)
RevenueUS$210.24m
Cost of RevenueUS$79.20m
Gross ProfitUS$131.04m
ExpensesUS$218.57m
Earnings-US$87.53m

Valuation

Is Amryt Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AMYT (£1.46) is trading below our estimate of fair value (£14.53)

Significantly Below Fair Value: AMYT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AMYT is unprofitable, so we can't compare its PE Ratio to the UK Pharmaceuticals industry average.

PE vs Market: AMYT is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AMYT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AMYT is good value based on its PB Ratio (2x) compared to the GB Pharmaceuticals industry average (4.5x).


Future Growth

How is Amryt Pharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

75.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AMYT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.9%).

Earnings vs Market: AMYT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AMYT's is expected to become profitable in the next 3 years.

Revenue vs Market: AMYT's revenue (27.2% per year) is forecast to grow faster than the UK market (4.9% per year).

High Growth Revenue: AMYT's revenue (27.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AMYT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Amryt Pharma performed over the past 5 years?

-0.3%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: AMYT is currently unprofitable.

Growing Profit Margin: AMYT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if AMYT's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare AMYT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AMYT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-20.6%).


Return on Equity

High ROE: AMYT has a negative Return on Equity (-28.6%), as it is currently unprofitable.


Financial Health

How is Amryt Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: AMYT's short term assets ($276.8M) exceed its short term liabilities ($153.8M).

Long Term Liabilities: AMYT's short term assets ($276.8M) do not cover its long term liabilities ($395.6M).


Debt to Equity History and Analysis

Debt Level: AMYT's net debt to equity ratio (23.9%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if AMYT's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AMYT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AMYT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Amryt Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AMYT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AMYT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AMYT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AMYT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AMYT's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Joe Wiley (50 yo)

6.83yrs

Tenure

US$1,719,000

Compensation

Dr. Joseph A. Wiley, also known as Joe, M.D. was the Founder of Amryt Pharma plc and serves as its Chief Executive Officer since 2015. He has been a Director at Amryt Pharma plc since April 19, 2016. Dr. W...


CEO Compensation Analysis

Compensation vs Market: Joe's total compensation ($USD1.72M) is above average for companies of similar size in the UK market ($USD1.03M).

Compensation vs Earnings: Joe's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: AMYT's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: AMYT's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 95.3%.


Top Shareholders

Company Information

Amryt Pharma plc's employee growth, exchange listings and data sources


Key Information

  • Name: Amryt Pharma plc
  • Ticker: AMYT
  • Exchange: AIM
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£451.559m
  • Shares outstanding: 318.00m
  • Website: https://www.amrytpharma.com

Number of Employees


Location

  • Amryt Pharma plc
  • 45 Mespil Road
  • 196 High Road
  • Dublin
  • Co. Dublin
  • 4
  • Ireland

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/01 18:48
End of Day Share Price2021/12/01 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.